Regeneron's phase 2 study of aflibercept co-formulated with rinucumabshows no benefit
Regeneron announced topline results from the Phase 2 CAPELLA study evaluating aflibercept co-formulated with rinucumab in patients with neovascular age-related macular degeneration. The combination therapy did not demonstrate an improvement in best corrected visual acuity. September 30, 2016